Protein kinase C-dependent phosphorylation in prenatally induced microencephaly
Related Experiment Video
Updated: Oct 13, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
F Cattabeni1, M Cinquanta, M Di Luca
1Institute of Pharmacological Sciences, University of Milano, Italy.
Abstract:
We describe here integrated studies conducted in an animal model of brain malformation induced by prenatal treatment with a potent antimitotic agent, methylazoxymethanol acetate (MAM). When given at gestational day 15, MAM induces a marked and dose-dependent hypoplasia of cortex and hippocampus. The alteration of specific neurotransmitter systems in these brain areas reflect the specificity of the damage induced by MAM administration at this particular stage of brain development. These animals, when adult, show impairments in learning and memory performance, without gross alterations of spontaneous behavior. The impairment in cognitive functions is correlated with changes, both in cortex and hippocampus, of the phosphorylation state of the neuron-specific protein B-50, a substrate of Protein Kinase C, known to play a key role in synaptic plasticity. Moreover, Long-Term Potentiation (LTP), a cellular model for studying synaptic plasticity associated with learning and memory, is impaired in the hippocampal subfields affected by MAM treatment. All these results--obtained with anatomical, behavioral, neurochemical and electrophysiological studies-point to the usefulness of this animal model to understand the long-lasting consequences of the interference of neurotoxic compounds with the developing CNS.
Insights
Prenatal exposure to methylazoxymethanol acetate (MAM) causes brain malformations, leading to impaired learning and memory in adult animals. This neurodevelopmental damage affects synaptic plasticity and protein B-50 phosphorylation.
Area of Science:
- Neuroscience
- Developmental Biology
- Toxicology
Background:
- Prenatal exposure to neurotoxic agents can cause lasting brain malformations.
- Methylazoxymethanol acetate (MAM) is a potent antimitotic agent that can induce developmental neurotoxicity.
- Understanding the long-term consequences of developmental neurotoxicity is crucial for public health.
Purpose of the Study:
- To investigate the long-lasting effects of prenatal MAM exposure on brain development and cognitive function.
- To characterize the neurobiological mechanisms underlying cognitive impairments induced by MAM.
- To validate an animal model for studying the impact of neurotoxic compounds on the developing central nervous system (CNS).
Main Methods:
- Induction of brain malformation in an animal model using prenatal MAM administration at gestational day 15.
- Anatomical, behavioral, neurochemical, and electrophysiological assessments in adult animals.
- Analysis of neurotransmitter systems, neuron-specific protein B-50 phosphorylation, and Long-Term Potentiation (LTP) in the cortex and hippocampus.
Main Results:
- MAM treatment induced dose-dependent hypoplasia of the cortex and hippocampus.
- Adult animals exhibited impaired learning and memory performance without gross behavioral alterations.
- Cognitive deficits correlated with altered B-50 protein phosphorylation and impaired hippocampal LTP.
Conclusions:
- Prenatal MAM exposure creates a valid animal model for studying developmental neurotoxicity.
- Interference with neurodevelopment by toxic compounds can lead to persistent cognitive impairments.
- The observed changes in synaptic plasticity mechanisms provide insights into the long-term effects of neurodevelopmental insults.
More Related Videos
Related Concept Videos
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
cAMP-dependent Protein Kinase Pathways

